Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 25,000 Shares of Aquestive ...
Alexander Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics Inc (NASDAQ:AQST), has sold 25,000 shares of the company on March 8, 2024, according to a recent SEC filing. The transaction was executed at an average price of $5.19 per share, resulting in a total value of $129,750.
Aquestive Therapeutics Inc is a pharmaceutical company focused on developing and commercializing differentiated products to address patients' unmet needs and improve their quality of life. The company utilizes its proprietary PharmFilm technology to develop oral film formulations for the delivery of medications.
Over the past year, the insider has sold a total of 25,000 shares of Aquestive Therapeutics Inc and has not made any purchases of the stock. The recent sale by Alexander Schobel represents the only insider sell transaction for the company in the past year, with no insider buys recorded during the same period.
Shares of Aquestive Therapeutics Inc were trading at $5.19 on the day of the insider's recent sale, giving the company a market capitalization of $374.57 million.
The stock's price-to-GF-Value ratio stands at 3.24, indicating that Aquestive Therapeutics Inc is significantly overvalued based on its GF Value. The GF Value is an intrinsic value estimate that considers historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling activity for Aquestive Therapeutics Inc.
The GF Value image above provides a visual representation of the stock's valuation in relation to its intrinsic value estimate.
For more detailed information on insider transactions and stock performance for Aquestive Therapeutics Inc (NASDAQ:AQST), investors and analysts are encouraged to visit the company's profile on GuruFocus.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
